Expected Key Milestones: Report early data from the VS-7375-101 trial in 1H 2026. Select the RP2D with cetuximab and initiate the CRC combination expansion cohort in 1H 2026. Complete enrollment in combination dose-escalation cohorts in mid-2026. Complete enrollment in monotherapy expansion cohorts in 2H 2026. Select the RP2D and plan to initiate the PDAC and NSCLC combination expansion cohorts in 2H 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- 3 Best Stocks With 125%+ Upside Ahead, According to Top Analysts, 3/2/2026
- VSTM Upcoming Earnings Report: What to Expect?
- Verastem price target raised to $18 from $15 at Mizuho
- 3 ‘Strong Buy’ Stocks to Buy Now, According to Top Analysts
- Verastem reports preliminary Q4 revenue $17.5M, consensus $16.53M